Swedish Orphan Biovitrum AB (OSTO:SOBI) Net Income (Continuing Operations) : kr2,140 Mil (TTM As of Mar. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Swedish Orphan Biovitrum AB Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Swedish Orphan Biovitrum AB's Net Income (Continuing Operations) for the three months ended in Mar. 2024 was kr800 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 was kr2,140 Mil.

Swedish Orphan Biovitrum AB Net Income (Continuing Operations) Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Net Income (Continuing Operations) Chart

Swedish Orphan Biovitrum AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income (Continuing Operations)

Get a 7-Day Free Trial

3,305.00

3,245.00

2,679.00

2,638.00

2,408.00

Swedish Orphan Biovitrum AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income (Continuing Operations)	Get a 7-Day Free Trial															1,067.00	221.00	94.00	1,025.00	800.00

Swedish Orphan Biovitrum AB Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr2,140 Mil.

Swedish Orphan Biovitrum AB (OSTO:SOBI) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Swedish Orphan Biovitrum AB Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Swedish Orphan Biovitrum AB (OSTO:SOBI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (OSTO:SOBI) » Definitions » Net Income (Continuing Operations)

Comparable Companies

Traded in Other Exchanges

SWOBY:USA BIOVF:USA SOBIs:UK 0MTD:UK B6E:Germany

Address

Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76

Website

https://www.sobi.com

Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Swedish Orphan Biovitrum AB (OSTO:SOBI) Headlines

No Headlines